

NIH AIDS Reagent Program

20301 Century Boulevard Building 6, Suite 200 Germantown, MD 20874 USA

Phone: 240 686 4740 Fax: 301 515 4015 aidsreagent.org

DATA SHEET

Anti-HIV-1 gp120 Monoclonal (4G10) Reagent:

Catalog Number: 2534

Lot Number: 100272

Release Category: D

Provided: 1 mL tissue culture supernatant.

Host: Balb/c splenocyte x Ag8658 myeloma.

Special Characteristics: Raised against hybrid HBcAg/HIV-1 gp120 (aa 303-327) particles. Recognizes LAI gp160 and the V3 peptide RIQRGPGRAFVTGK (aa 308-322) in ELISA. Also recognizes gp120 in Western blots and IFA of LAI-infected H9 cells. The antibody inhibits syncytium formation, RT activity, and p24 production in vitro (100% over 20 days).

ARP3012 4G10 Mab Recognizing ARP656 HIV-1 gp160 protein.

Endotoxin: 17.152 EU/mL*

*NOTE: Endotoxin has been shown to induce chemokines and other soluble HIV and SIV inhibitory factors in primary cultures of PBMC, monocytes and macrophages (Verani et al., J Exp Med 185:805-816, 1997; J Immunol 168:6388-6396, 2002; Montefiori in preparation). Thus, caution is advised when using this reagent for in vitro studies

involving primary cells.

Recommended Storage:

Keep at 4°C for short term storage and -80°C for long term storage. Avoid freeze-thaw

cycles as reagent degradation may result.

Contributor: Dr. Albrecht von Brunn, Courtesy of the MRC AIDS Directed Programme.

Isotype: IgG₁.

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 12/08/2017 Page 1 of 2 References:

von Brunn A, Brand M, Reichhuber C, Morys-Wortman C, Deinhardt F, Schödel F. Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the

surface of hepatitis B core particles. Vaccine 11:817-824, 1993.

von Brunn A, Reichhuber C, Brand M, Bechowsky B, Gürtler L, Eberle J, Kleinschmidt A, Erfle V, Schödel F. The principal neutralizing determinant (V3) of HIV-1 induces HIV-1-neutralizing antibodies upon expression on HBcAg particles. In: Vaccines 93,

Cold Spring Harbor Press; Cold Spring Harbor, New York, pp 159-165, 1993.

NOTE:

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 $\,$ gp120 Monoclonal (4G10) from Dr. Albrecht von Brunn, Courtesy of the MRC AIDS Directed Programme." Also include the references cited above in any publications.

Last Updated December 08, 2017

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

REV: 12/08/2017 Page 2 of 2